Stock Market Reviews

NBIX (Neurocrine Biosciences, Inc.) News

Get the latest news, insights, and market updates on NBIX (Neurocrine Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.
  Jan 5, 2026 - $NBIX
• Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not meet primary or key secondary endpoints. The primary objective of the study was to assess improvement in chorea, a type of involuntary movement, in individuals with DCP.
  Dec 22, 2025 - $NBIX
• Exploring Three High Growth Tech Stocks In The US Market
  Amidst a backdrop of declining major stock indexes, with the S&P 500 and Dow Jones Industrial Average experiencing their fourth consecutive losses due to AI bubble concerns and tepid labor data, the tech-heavy Nasdaq has also seen a recent decline. In this environment, identifying high-growth tech stocks requires careful consideration of companies that demonstrate resilience and potential for innovation despite broader market challenges.
  Dec 17, 2025 - $NBIX
• Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value. Neurocrine highlighted this business strategy during its 2025 R&D Day at its headquarters in San Diego, CA.
  Dec 16, 2025 - $NBIX
• Neurocrine Biosciences to Host R&D Day on December 16
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego.
  Dec 9, 2025 - $NBIX
• Three Stocks That Could Be Undervalued By Market Estimates In December 2025
  As we enter December 2025, the U.S. stock market presents a mixed picture with major indices like the Dow and S&P 500 hovering near all-time highs while investors closely monitor upcoming inflation data that could influence Federal Reserve decisions on interest rates. In this environment, identifying undervalued stocks requires careful consideration of market dynamics and economic indicators, as these factors can reveal opportunities where current valuations may not fully reflect a company's...
  Dec 5, 2025 - $NBIX
• Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level
  Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone.
  Dec 5, 2025 - $NBIX
• Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication
  Neurocrine Biosciences (NBIX) recently caught attention with the publication of a comprehensive peer-reviewed review that brings together more than ten years of research on its VMAT2 inhibitors for tardive dyskinesia. This kind of analysis often sparks renewed discussion about clinical data and product differentiation among both medical professionals and market watchers. See our latest analysis for Neurocrine Biosciences. Off the back of this major review, the momentum behind Neurocrine...
  Nov 28, 2025 - $NBIX
• Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now
  Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
  Nov 27, 2025 - $NBIX
• Neurocrine (NBIX) Q3 2025 Earnings Call Transcript
  Kyle Gano: Thank you, Todd. From a commercial perspective, for INGREZZA, the recent investments to expand our sales force and improve patient access drove yet another record quarter for both new patient starts and total prescriptions.
  Nov 27, 2025 - $NBIX